Ambio Life Sciences

Ambio Life Sciences is a global leader in integrative ibogaine treatment, offering medically supervised psychedelic-assisted therapies for addiction, trauma, traumatic brain injury, chronic pain, and neurodegenerative conditions. The company has pioneered protocols for complex cases and published the first human clinical trial of ibogaine for traumatic brain injury in Navy SEALs with significant improvements in disability measures and mental health outcomes. In 2025 they launched the world’s first structured clinical program using ibogaine for neurodegenerative diseases such as Parkinson’s disease and multiple sclerosis[4][5].